ClinicalTrials.gov
public full text
Public Domain
Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody therapy in treating patients who have stage III or stage IV melanoma at high risk for recurrence following surgery to remove the tumor.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Melanoma or Brain Tumors#1365166
- Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer#1139309
- Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer#1228418
- Monoclonal Antibody Therapy in Treating Patients With Brain Metastases#1363903
- Interim FDG PET-CT in Melanoma Metastatic Patient's Treated by Anti-PD1 Therapy#1087175
Record · ID 1183603
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive